Wen-Hong Xu
Overview
Explore the profile of Wen-Hong Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhong X, Shi M, Liu H, Chen J, Wang T, Lin M, et al.
Pharm Dev Technol
. 2020 Oct;
26(1):21-29.
PMID: 33070673
Multidrug resistance (MDR) is a serious challenge in chemotherapy and also a major threat to breast cancer treatment. As an intracellular energy factory, mitochondria provide energy for drug efflux and...
2.
Lin C, Wang K, Xu F, Liu Y, Li J, Pan C, et al.
Breast J
. 2020 May;
26(9):1871-1873.
PMID: 32449220
No abstract available.
3.
Guo Y, Lu Y, Jia Y, Qu H, Qi D, Wang X, et al.
Aging Dis
. 2020 Feb;
11(1):44-59.
PMID: 32010480
Many oncogenes are involved in the progression from low-grade squamous intraepithelial lesions (LSILs) to high-grade squamous intraepithelial lesions (HSILs); which greatly increases the risk of cervical cancer (CC). Thus, a...
4.
Wang T, Wei Q, Zhang Z, Lin M, Chen J, Zhou Y, et al.
Biomater Sci
. 2019 Nov;
8(1):118-124.
PMID: 31777865
On account of the biological significance of self-assembling peptides in blocking the cellular mass exchange as well as impeding the formation for actin filaments resulting in program cell death, stimuli-responsive...
5.
Zhong X, Xu W, Wang Z, Guo W, Chen J, Guo N, et al.
Drug Dev Ind Pharm
. 2019 Jul;
45(9):1556-1564.
PMID: 31271317
This study was aimed to develop DOX-TPP loaded acetal-PEG-PCCL micelles to improve the clinical efficacy of drug resistance tumor. Chemotherapy is one of the main treatments for breast cancer but...
6.
Zhang Z, Huang-Fu M, Xu W, Han M
Eur J Pharm Biopharm
. 2019 Feb;
137:122-130.
PMID: 30776412
The tumor microenvironment is the cellular environment that is also described as the "soil" for supporting tumor growth, proliferation, invasion and metastasis, as well as protecting tumor cells from immunological...
7.
Liu H, Guo N, Guo W, Huang-Fu M, Vakili M, Chen J, et al.
Acta Pharmacol Sin
. 2018 Jun;
39(10):1681-1692.
PMID: 29849132
Breast cancer is the leading cause of cancer-related death for women, and multidrug resistance (MDR) is the major obstacle faced by chemotherapy for breast cancer. We have previously synthesized a...
8.
Liu H, Guo N, Wang T, Guo W, Lin M, Huang-Fu M, et al.
Mol Pharm
. 2018 Jan;
15(3):882-891.
PMID: 29357260
Multidrug resistance (MDR) is the major obstacle for chemotherapy. In a previous study, we have successfully synthesized a novel doxorubicin (DOX) derivative modified by triphenylphosphonium (TPP) to realize mitochondrial delivery...
9.
Xu J, Shen L, Zhang B, Xu W, Ruan S, Pan C, et al.
Oncol Lett
. 2017 Jan;
12(6):5363-5369.
PMID: 28105244
Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that has been demonstrated to be clinically useful for the treatment of patients with non-small cell lung cancer...
10.
Xu J, Zhang B, Li X, Xu W, Zhou J, Shen L, et al.
Discov Med
. 2016 Sep;
22(119):7-17.
PMID: 27585226
Multidrug resistance (MDR) to Doxorubicin (DOX) remains a major obstacle to successful cancer treatment. The present study sought to overcome the MDR of lung cancer cells and achieve radiosensitization by...